Doptelet (Avatrombopag)
Thrombopoietin receptor agonist for thrombocytopenia
Doptelet (avatrombopag) is a prescription thrombopoietin receptor agonist that helps increase platelet counts in the blood. It is approved for treating low platelet counts (thrombocytopenia) in adults with chronic liver disease before a medical procedure, and in adults with chronic immune thrombocytopenia (ITP) when prior treatments have been insufficient.
Quick Facts
Key Takeaways
- Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by activating TPO receptors on bone marrow progenitor cells.
- It is approved for two indications: thrombocytopenia in chronic liver disease (CLD) before planned procedures and chronic immune thrombocytopenia (ITP) in adults.
- For CLD, treatment is a short 5-day course (40-60 mg/day) started 10-13 days before a planned procedure.
- For chronic ITP, the usual starting dose is 20 mg once daily, with dose adjustments based on platelet count monitoring.
- Thromboembolic events are a recognized risk; patients should be monitored closely, especially those with existing risk factors for blood clots.
What Is Doptelet and What Is It Used For?
Doptelet contains the active substance avatrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists (TPO-RAs). These medications work by mimicking the action of thrombopoietin, a naturally occurring hormone that regulates platelet production in the body. By binding to and activating the TPO receptor on megakaryocyte progenitor cells in the bone marrow, avatrombopag stimulates the proliferation and differentiation of megakaryocytes, ultimately leading to increased platelet production.
Platelets are small blood cells that play a critical role in hemostasis, the process by which the body stops bleeding. When platelet counts are too low, a condition known as thrombocytopenia, patients face an increased risk of bleeding. This can be particularly problematic when invasive medical procedures are planned, as even routine procedures may carry significant bleeding risks in patients with low platelet counts.
Avatrombopag is a small molecule that is structurally distinct from other TPO receptor agonists. It was specifically designed to interact with the transmembrane domain of the TPO receptor, triggering intracellular signaling cascades (including JAK2, STAT5, and MAPK pathways) that promote megakaryocyte growth and maturation. This mechanism of action is complementary to endogenous TPO, meaning avatrombopag can enhance platelet production even in patients who already have circulating thrombopoietin.
Chronic Liver Disease (CLD) Indication
Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure that carries a risk of bleeding. Chronic liver disease frequently leads to thrombocytopenia through multiple mechanisms, including decreased thrombopoietin production by the liver, increased platelet sequestration in the spleen (hypersplenism), and accelerated platelet destruction. Historically, platelet transfusions were the primary option for raising platelet counts before procedures, but they carry risks including transfusion reactions, alloimmunization, and transfusion-transmitted infections.
Clinical trials, particularly the ADAPT-1 and ADAPT-2 studies, demonstrated that avatrombopag significantly reduced the proportion of patients requiring platelet transfusions or rescue procedures for bleeding compared to placebo. In these pivotal phase 3 trials, patients with chronic liver disease and platelet counts below 50 × 109/L were randomized to receive avatrombopag or placebo for 5 days before a scheduled procedure. The results showed that a significantly higher proportion of avatrombopag-treated patients achieved the target platelet count and did not require platelet transfusion or rescue therapy, establishing avatrombopag as an effective oral alternative to platelet transfusions for periprocedural thrombocytopenia management.
Chronic Immune Thrombocytopenia (ITP) Indication
Doptelet is also approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ITP is an autoimmune disorder characterized by immune-mediated platelet destruction and often inadequate platelet production. First-line treatments typically include corticosteroids and intravenous immunoglobulin (IVIg), but many patients either fail to respond or relapse after initial treatment.
The pivotal phase 3 study for the ITP indication demonstrated that avatrombopag produced durable platelet responses in patients with chronic ITP who had previously received at least one treatment. Unlike some other TPO-RAs, avatrombopag does not require dietary restrictions (such as avoiding calcium-rich foods or dairy products that can interfere with absorption) and can be taken with any type of food, which may improve treatment adherence and reduce variability in drug absorption.
The ability to take Doptelet without food restrictions represents a meaningful advantage in clinical practice. For patients with chronic ITP who may need long-term daily treatment, minimizing the burden of dietary restrictions can improve quality of life and treatment compliance. Additionally, avatrombopag has shown consistent pharmacokinetic properties regardless of the type of food consumed, providing more predictable drug exposure compared to some alternatives.
What Should You Know Before Taking Doptelet?
Before starting treatment with Doptelet, it is essential to have a thorough discussion with your healthcare provider about your medical history, current medications, and any risk factors that may affect the safety and efficacy of the treatment. This section outlines the key considerations that should be addressed before taking Doptelet.
Contraindications
Doptelet is contraindicated in patients with a known hypersensitivity to avatrombopag or to any of the excipients listed in the composition. Allergic reactions have been reported post-marketing, including facial swelling, tongue swelling, and skin changes such as rash and itching. If you experience any signs of an allergic reaction while taking Doptelet, discontinue the medication and seek medical attention immediately.
While not a formal contraindication, Doptelet should be used with extreme caution in patients with myelodysplastic syndrome (MDS). TPO receptor agonists may stimulate the proliferation of myeloid blast cells, potentially worsening the underlying condition or accelerating progression to acute myeloid leukemia. If you have a known or suspected bone marrow disorder, your doctor should carefully weigh the potential risks and benefits before prescribing Doptelet and should consider alternative approaches to managing thrombocytopenia.
Warnings and Precautions
Doptelet may increase the risk of thromboembolic events (blood clots). This risk may be higher in patients who are elderly, immobile for prolonged periods, have cancer, take oral contraceptives or hormone replacement therapy, have recently undergone surgery or injury, are significantly overweight, smoke, or have advanced chronic liver disease. Discuss all risk factors with your doctor before starting treatment.
Before starting Doptelet, inform your healthcare provider if you or a family member have a history of blood clots in veins or arteries. Thromboembolic events reported with avatrombopag include portal vein thrombosis (in patients with CLD), deep vein thrombosis, pulmonary embolism, cerebrovascular events (stroke and transient ischemic attacks), and myocardial infarction (in patients with ITP). The risk of thrombosis should be carefully balanced against the benefits of increasing platelet counts.
Platelet count monitoring: If you stop taking Doptelet, your platelet count will likely decrease to pre-treatment levels or even lower within days, increasing the risk of bleeding. This rebound thrombocytopenia can occur within 1-2 weeks of discontinuation and may be more severe than the baseline thrombocytopenia. Your doctor will monitor your platelet counts closely during and after treatment and will discuss appropriate precautions with you.
Bone marrow monitoring: In patients with bone marrow abnormalities, medications like Doptelet may worsen these problems by stimulating fibrosis (scarring) of the bone marrow. Signs of bone marrow changes may appear as abnormal blood test results, including the development of teardrop-shaped red blood cells or immature blood cells in the peripheral blood. Your doctor may perform bone marrow biopsies to monitor for reticulin or collagen fibrosis during prolonged treatment, particularly in patients with chronic ITP receiving long-term therapy.
Children and Adolescents
Doptelet should not be given to patients under 18 years of age. The safety and efficacy of this medication in the pediatric population have not been established through clinical trials. There are currently insufficient data to support dosing recommendations in children and adolescents. Clinical research in pediatric populations is ongoing, and future labeling updates may include recommendations for younger patients as data become available.
Pregnancy and Breastfeeding
Doptelet is not recommended during pregnancy. Women of childbearing potential should use effective contraception while taking this medication. There are no adequate and well-controlled studies of avatrombopag in pregnant women. Animal reproduction studies have shown adverse developmental effects at doses that produced maternal toxicity. If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before taking this medication. Your doctor will assess whether the potential benefits of treatment outweigh the potential risks to the fetus.
It is not known whether avatrombopag or its metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded based on the available data. Your doctor will help you weigh the benefits of breastfeeding against the potential risks to your child, considering the importance of the medication to the mother and the potential for serious adverse reactions in nursing infants.
Driving and Operating Machinery
Doptelet is not expected to have a significant effect on your ability to drive or use machines based on its pharmacological properties. However, some patients may experience dizziness, fatigue, or visual disturbances, which are known side effects of the medication. If you experience these symptoms, exercise caution when driving, cycling, or operating machinery until you know how the medication affects you personally.
Lactose Content
Doptelet contains lactose monohydrate as an excipient in the tablet core. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Doptelet to discuss whether this medication is appropriate for you.
How Does Doptelet Interact with Other Drugs?
Drug interactions with Doptelet are an important consideration for safe and effective treatment. While avatrombopag has a relatively favorable interaction profile compared to some other TPO receptor agonists (notably, it does not chelate polyvalent cations and therefore does not require separation from calcium, magnesium, or iron-containing products), there are still clinically relevant interactions that healthcare providers and patients should be aware of.
Avatrombopag is primarily metabolized by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver. This means that drugs affecting these metabolic pathways can potentially alter the blood levels of avatrombopag, either increasing its effects and side effects or reducing its therapeutic efficacy.
Important Interactions
If you are taking other medications for ITP, such as corticosteroids, immunoglobulins, rituximab, or other TPO receptor agonists (eltrombopag or romiplostim), your doctor may need to adjust doses or taper concurrent medications when starting Doptelet. The concomitant use of multiple platelet-elevating therapies may increase the risk of excessive platelet counts and subsequent thromboembolic events. Close monitoring of platelet counts is essential during any transition between therapies.
Medications that are dual inhibitors of both CYP2C9 and CYP3A4 (such as fluconazole) may increase avatrombopag exposure, potentially leading to higher platelet counts and increased risk of adverse effects. Conversely, strong inducers of CYP2C9 and CYP3A4 (such as rifampin, an antibiotic used for tuberculosis) may significantly decrease avatrombopag exposure, potentially reducing its ability to raise platelet counts to therapeutic levels.
| Interacting Drug/Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Dual CYP2C9/CYP3A4 inhibitors (e.g., fluconazole) | Increased avatrombopag exposure | Moderate | Monitor platelet counts more frequently; consider dose reduction if needed |
| Strong CYP2C9/CYP3A4 inducers (e.g., rifampin) | Decreased avatrombopag exposure | Moderate | Consider dose adjustment; monitor platelet response closely |
| Other ITP treatments (corticosteroids, IVIg, rituximab) | Additive platelet-elevating effect | High | May need dose reduction or tapering of concomitant therapy |
| Anticoagulants (warfarin, heparin, DOACs) | Complex effect on hemostasis | Moderate | Monitor closely; individualize dosing based on clinical status |
| Antiplatelet agents (aspirin, clopidogrel) | Altered bleeding/thrombosis balance | Moderate | Clinical monitoring recommended; assess bleeding/clotting risk |
Always inform your healthcare provider about all medications, dietary supplements, and herbal products you are taking before starting Doptelet. This includes over-the-counter medications such as aspirin, ibuprofen, naproxen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) that may affect platelet function or increase bleeding risk. While Doptelet does not have a known significant interaction with most common medications, individual patient factors may influence the overall risk-benefit profile.
What Is the Correct Dosage of Doptelet?
Doptelet should always be taken exactly as prescribed by your doctor or pharmacist. The dosing regimen differs significantly depending on whether you are being treated for thrombocytopenia associated with chronic liver disease or for chronic immune thrombocytopenia. The tablets should be swallowed whole with food, at the same time each day, to ensure optimal and consistent drug absorption.
Dosage for Chronic Liver Disease (CLD)
CLD Dosing Schedule
Doptelet is available as 20 mg film-coated tablets. The dose is determined by your platelet count before treatment begins:
- Platelet count <40 × 109/L: 60 mg (3 tablets) once daily for 5 consecutive days
- Platelet count 40 to <50 × 109/L: 40 mg (2 tablets) once daily for 5 consecutive days
Treatment should be started 10 to 13 days before the planned procedure. The scheduled medical procedure should be performed 5 to 8 days after the last dose of Doptelet to coincide with the expected peak platelet response. Your doctor or pharmacist will tell you exactly how many tablets to take and when to start treatment.
The 5-day treatment course was carefully designed based on pharmacokinetic and pharmacodynamic studies showing that this duration optimally stimulates megakaryocyte proliferation while allowing sufficient time for mature platelets to be released into the circulation before the planned procedure. The timing of the procedure (5-8 days after the last dose) is critical, as platelet counts typically peak during this window.
Dosage for Chronic Immune Thrombocytopenia (ITP)
ITP Dosing Schedule
The usual starting dose is 20 mg (1 tablet) once daily. If you are taking certain other medications that may affect avatrombopag metabolism, your starting dose may need to be adjusted. Your doctor will monitor your platelet count regularly and adjust the dose as needed.
The treatment goal for chronic ITP is to achieve the lowest dose of Doptelet that maintains a platelet count sufficient to reduce the risk of clinically significant bleeding (generally ≥50 × 109/L) while minimizing the risk of thromboembolic events from excessive platelet counts.
| Indication | Starting Dose | Duration | Monitoring |
|---|---|---|---|
| CLD (platelets <40 × 10⁹/L) | 60 mg/day (3 tablets) | 5 days | Platelet count before procedure |
| CLD (platelets 40-<50 × 10⁹/L) | 40 mg/day (2 tablets) | 5 days | Platelet count before procedure |
| Chronic ITP | 20 mg/day (1 tablet) | Ongoing (long-term) | Regular platelet counts; dose titration |
Missed Dose
If you forget to take a dose of Doptelet, take it as soon as you remember and then take your next dose at the usual scheduled time. Do not take a double dose to make up for a forgotten dose, as this could lead to excessively high platelet counts. If you are unsure about what to do after missing a dose, contact your doctor or pharmacist for guidance. For patients with CLD, missing a dose during the short 5-day treatment course is particularly important to address promptly, as it may affect the timing and adequacy of the platelet response before the planned procedure.
Overdose
If you take more Doptelet than prescribed, contact your doctor, pharmacist, or poison control center immediately. Excessive doses may lead to excessively high platelet counts (thrombocytosis), which can significantly increase the risk of thromboembolic complications including deep vein thrombosis, pulmonary embolism, stroke, or heart attack. There is no specific antidote for avatrombopag overdose. Treatment should be symptomatic and supportive, with close monitoring of platelet counts and clinical status. Hemodialysis is not expected to be effective in removing avatrombopag due to its high protein binding.
Stopping Treatment
Do not stop taking Doptelet unless your doctor tells you to do so. Abruptly stopping Doptelet in patients with chronic ITP can lead to a rapid decline in platelet counts, potentially to levels lower than before treatment (rebound thrombocytopenia). This can occur within days of discontinuation and may increase the risk of serious bleeding. Your doctor will develop a plan for discontinuation if needed, which may include closer monitoring and alternative treatments during the transition period.
Always take Doptelet with food to ensure optimal absorption. Swallow the tablets whole; do not crush, break, or chew them. Take your dose at the same time each day to maintain consistent drug levels in your body. For CLD patients, it is essential to complete the full 5-day treatment course and schedule your procedure within the recommended 5-8 day window after the last dose. Unlike some other TPO-RAs, Doptelet can be taken with any type of food without restrictions.
What Are the Side Effects of Doptelet?
Like all medicines, Doptelet can cause side effects, although not everybody gets them. The side effect profile differs depending on the indication for which Doptelet is being used, primarily because the treatment duration and dosing differ between the two approved indications. Understanding these potential side effects helps you recognize when to seek medical attention and when side effects may be manageable with your doctor's guidance.
Side Effects in Chronic Liver Disease (CLD)
In patients with chronic liver disease, the side effect profile of Doptelet is relatively favorable, likely reflecting the short treatment duration of only 5 days. Clinical trial data from the ADAPT-1 and ADAPT-2 studies showed that the overall incidence of adverse events was similar between avatrombopag and placebo groups. The following side effects have been reported:
Common
- Fatigue (tiredness)
Uncommon
- Low red blood cell count (anemia)
- Blood clot in the portal vein (may cause pain or swelling in the upper abdomen)
- Bone pain
- Muscle pain (myalgia)
- Fever (pyrexia)
Not Known
- Allergic reactions including facial swelling, tongue swelling, and skin changes (rash, itching)
Side Effects in Chronic Immune Thrombocytopenia (ITP)
In patients with chronic ITP who receive longer-term daily treatment, a broader and more comprehensive range of side effects has been identified through clinical trials and post-marketing surveillance. This reflects both the extended duration of therapy and the larger patient population studied over time.
Very Common
- Fatigue (tiredness)
- Headache
Common
- Back pain, muscle pain, joint pain, pain in arms or legs
- Musculoskeletal discomfort (bones, muscles, ligaments, tendons, nerves)
- Nausea, diarrhea, vomiting, abdominal pain, flatulence
- Dizziness, head discomfort, migraine
- Decreased appetite
- Weakness (asthenia)
- Nosebleeds (epistaxis)
- Skin rash, itching (pruritus), acne, petechiae (red skin spots)
- Tingling or numbness (paresthesia)
- Enlarged spleen (splenomegaly)
- Shortness of breath (dyspnea)
- Elevated blood pressure (hypertension)
- Tendency to bruise or bleed (low platelet count)
Common (Blood Test Abnormalities)
- Elevated lipids (cholesterol, triglycerides)
- Elevated or decreased blood sugar (glucose)
- Elevated liver enzyme (alanine aminotransferase, ALT)
- Elevated lactate dehydrogenase (LDH)
- Elevated gastrin levels
- Decreased red blood cell count (anemia)
- Increased or decreased platelet count
Uncommon
- Superficial vein thrombosis (redness, swelling, pain in a vein due to a blood clot)
- Deep vein thrombosis (pain, swelling, tenderness in leg, usually the calf)
- Blood clots in cerebral veins
- Vasoconstriction (narrowing of blood vessels)
- Pulmonary embolism (sudden shortness of breath with sharp chest pain and/or rapid breathing)
- Obstruction or narrowing of the vein that carries blood to the liver (hepatic vein thrombosis)
- Stroke or transient ischemic attack (mini-stroke)
- Heart attack (myocardial infarction)
- Irregular heartbeat (arrhythmia)
- Hemorrhoids; dilated rectal veins
- Upper respiratory tract infection (sinusitis, pharyngitis, tonsillitis)
- Bone marrow fibrosis (scarring in the bone marrow)
- Dehydration
- Increased appetite; hunger
- Mood changes; abnormal thinking
- Changes in taste, hearing, or vision
- Eye problems (irritation, discomfort, itching, swelling, tearing, light sensitivity, blurred vision, decreased vision, vision loss)
- Ear pain; increased sensitivity to everyday sounds
- Bloody sputum; nasal congestion
- Constipation; belching; acid reflux; burning or stinging sensation in the mouth
- Mouth numbness; tongue swelling; tongue problems
- Hair loss (alopecia); boils; dry skin
- Purple-dark spots on the skin (blood leaking from vessels, bruises)
- Excessive sweating; changes in skin color; itchy rash; skin irritation
- Joint abnormalities; muscle cramps; muscle weakness
- Blood in urine; heavy menstrual bleeding
- Nipple pain; chest pain
- Pain; swelling in arms or legs (edema)
Uncommon (Blood Test Abnormalities)
- Bacteria in the blood (bacteremia)
- Increased white blood cell count
- Decreased iron levels in the blood
- Elevated liver enzyme (aspartate aminotransferase, AST)
- Abnormal liver function test results
Not Known
- Allergic reactions including facial swelling, tongue swelling, and skin changes (rash, itching)
Seek immediate medical help if you experience: sudden shortness of breath with sharp chest pain (possible pulmonary embolism), one-sided weakness, difficulty speaking or sudden confusion (possible stroke), severe abdominal pain with swelling (possible portal vein thrombosis or hepatic vein thrombosis), sudden severe chest pain radiating to the arm or jaw (possible heart attack), or signs of a severe allergic reaction including facial swelling and difficulty breathing.
It is important to report any suspected side effects to your healthcare provider, even if they seem minor. Ongoing monitoring of side effects after a medicine has been authorized allows continued assessment of the benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national medicines regulatory authority (such as the FDA in the United States or the EMA in Europe).
How Should You Store Doptelet?
Doptelet does not require any special storage conditions, which makes it convenient for home storage. There is no need for refrigeration or protection from light beyond the original packaging. Keep this medicine out of the sight and reach of children at all times to prevent accidental ingestion.
Do not use Doptelet after the expiry date stated on the carton and on each blister pack after "EXP." The expiry date refers to the last day of the stated month. Using medication past its expiry date may result in reduced efficacy or altered safety profile, so always check the date before taking a dose.
Proper disposal of medications is important for environmental protection and public safety. Do not dispose of Doptelet via wastewater (down the toilet or drain) or with household waste (in the trash). Ask your pharmacist about medication take-back programs or other approved disposal methods in your area. These measures help protect the environment and prevent accidental exposure to others, including children and pets.
What Does Doptelet Contain?
Active Ingredient
The active substance is avatrombopag. Each film-coated tablet contains avatrombopag maleate equivalent to 20 mg avatrombopag. Avatrombopag maleate is the salt form of the active drug, which provides optimal stability and bioavailability characteristics for oral administration. Once ingested, the maleate salt dissociates and avatrombopag is absorbed through the gastrointestinal tract.
Inactive Ingredients (Excipients)
The other ingredients in Doptelet serve various pharmaceutical purposes to ensure tablet integrity, appropriate disintegration, consistent drug release, and protective coating:
- Tablet core: Lactose monohydrate (filler/binder), microcrystalline cellulose [E460(i)] (filler/binder), crospovidone type B [E1202] (disintegrant), colloidal anhydrous silica [E551] (glidant), magnesium stearate [E470b] (lubricant)
- Film coating: Polyvinyl alcohol [E1203] (film-forming agent), talc [E553b] (anti-tacking agent), macrogol 3350 [E1521] (plasticizer), titanium dioxide [E171] (opacifier/white colorant), yellow iron oxide [E172] (colorant)
Appearance and Packaging
Doptelet 20 mg film-coated tablets are pale yellow, round, and biconvex (curved on both top and bottom surfaces). Each tablet is debossed with "AVA" on one side and "20" on the other, allowing easy identification. The tablets are packaged in cartons containing one or two aluminum blister cards. Each blister card contains either 10 or 15 tablets, providing flexibility in packaging sizes to match different treatment regimens and durations.
Frequently Asked Questions About Doptelet
Doptelet (avatrombopag) has several distinguishing features compared to other TPO receptor agonists like eltrombopag (Revolade/Promacta) and romiplostim (Nplate). Unlike eltrombopag, avatrombopag does not chelate polyvalent cations and therefore does not require dietary restrictions (such as avoiding calcium-rich foods, dairy products, or mineral supplements within several hours of dosing). Additionally, avatrombopag is available only as an oral tablet, while romiplostim is administered as a weekly subcutaneous injection. Doptelet is also the only oral TPO-RA approved specifically for periprocedural thrombocytopenia management in patients with chronic liver disease.
In patients with chronic liver disease, platelet counts typically begin to rise within a few days of starting Doptelet, with peak platelet counts usually achieved approximately 10-13 days after the first dose. This is why the medication is started 10-13 days before a planned procedure. In patients with chronic ITP, the onset and magnitude of platelet count response may vary between individuals, but significant increases are typically observed within the first 1-2 weeks of treatment. Your doctor will monitor your platelet counts regularly to assess and optimize your response.
There are no specific drug-alcohol interactions listed in the Doptelet prescribing information. However, since Doptelet is commonly prescribed for patients with chronic liver disease, alcohol consumption is generally strongly discouraged as it can cause further liver damage and worsen liver function. Additionally, alcohol can impair platelet function and increase bleeding risk independently. Discuss your alcohol consumption with your doctor, as recommendations will depend on your individual medical circumstances and the indication for which you are taking Doptelet.
If your platelet count exceeds the upper limit of normal during treatment with Doptelet, your doctor will likely reduce the dose or temporarily discontinue the medication. Excessively high platelet counts (thrombocytosis) can significantly increase the risk of thromboembolic events, including deep vein thrombosis, pulmonary embolism, stroke, and heart attack. This is one of the most important safety considerations with any TPO receptor agonist. Regular platelet count monitoring is essential to guide dose adjustments and ensure your platelet count stays within the safe and effective target range.
No, Doptelet is not a cure for immune thrombocytopenia (ITP). It is a treatment that helps manage the condition by stimulating the bone marrow to produce more platelets. When Doptelet is discontinued, platelet counts typically return to pre-treatment levels or may even drop lower temporarily (rebound thrombocytopenia). Chronic ITP is an ongoing autoimmune condition, and many patients require long-term treatment to maintain adequate platelet counts. Your hematologist will work with you to determine the best long-term management strategy for your specific situation.
No, Doptelet is not suitable for emergency or urgent procedures. The medication requires a 5-day treatment course followed by a 5-8 day waiting period before the procedure, meaning a minimum lead time of approximately 10 days is needed. For emergency situations requiring immediate platelet count elevation, platelet transfusions remain the standard of care as they provide virtually instant platelet count increases. Doptelet is designed specifically for planned, elective procedures where there is adequate time for the drug to stimulate endogenous platelet production.
References
- European Medicines Agency (EMA). Doptelet (avatrombopag) - Summary of Product Characteristics. Last updated 2024. Available at: EMA - Doptelet EPAR
- U.S. Food and Drug Administration (FDA). Doptelet (avatrombopag) - Full Prescribing Information. AkaRx, Inc. / Sobi.
- Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155(3):705-718. doi:10.1053/j.gastro.2018.05.025
- Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. British Journal of Haematology. 2018;183(3):479-490. doi:10.1111/bjh.15573
- Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Therapeutic Advances in Hematology. 2019;10:2040620719841735. doi:10.1177/2040620719841735
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023. Geneva: World Health Organization.
- British National Formulary (BNF). Avatrombopag. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
Editorial Team
This article has been written by the iMedic Medical Editorial Team and reviewed by specialist physicians in hematology and clinical pharmacology. All medical claims are supported by peer-reviewed evidence and follow international guidelines from the EMA, FDA, WHO, and the American Society of Hematology (ASH). Our content undergoes rigorous fact-checking using the GRADE evidence framework.
iMedic Medical Editorial Team - specialists in hematology, hepatology, and clinical pharmacology with extensive experience in thrombotic and bleeding disorders.
iMedic Medical Review Board - independent panel of board-certified physicians who review all content according to EMA, FDA, and WHO guidelines.
Last medically reviewed:
Sources: EMA SmPC, FDA Prescribing Information, peer-reviewed clinical trials (ADAPT-1, ADAPT-2), ASH/ITP Guidelines, WHO Essential Medicines List, British National Formulary (BNF).